Pharma BD Deal Intelligence
Pfizer bought a TLR9/vaccine-adjuvant platform whose lead asset had already failed in Phase 3, then shuttered the whole unit three years later with no product ever reaching market.
Full analysis, sources & comparables →CpG 7909/PF-3512676 was being developed across NSCLC, renal cell carcinoma, lymphoma, melanoma, and as adjuvant for hepatitis B and influenza vaccines—broad…
Pfizer buys Coley for $164M, gaining its Toll-like receptor immunomodulator platform; coverage notes the buyout follows Pfizer's earlier discontinuation of the…
Pfizer paid a sizeable premium ($8 vs ~$3 prior close) just months after halting the Phase 3 NSCLC trial for PF-3512676—signaling a platform bet rather than a…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Pfizer agreed to acquire Coley Pharmaceutical Group for $8.00 per share (approximately $164 million) to add TLR-9 agonist immunomodulators to its pipeline. The tender offer expired December 28, 2007.
Pfizer bought a TLR9/vaccine-adjuvant platform whose lead asset had already failed in Phase 3, then shuttered the whole unit three years later with no product ever reaching market.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Coley Pharmaceutical Group Inc. (this deal) | 2007 | $164M | 13 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2007 deals · Pfizer Inc. deals